New data a boost for Johnson & Johnson and Bavarian Nordic's Ebola vaccine

The Lancet has published new data on Johnson & Johnson and Bavarian Nordic's combined vaccine against Ebola, which according to the US life science group strongly supports preventatitve use of the vaccine.

Healthcare professionals on the Ivory Coast are being vaccinated after ebola was found in the country. | Photo: Luc Gnago/Reuters/Ritzau Scanpix

Results from two new studies that have recently been published by medical journal The Lancet are a cause for celebration at Johnson & Johnson.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs